Company research
PRECISION BIOSCIENCES INC
CIK 1357874Updated Sep 26, 2026
SecurityDTIL · NASDAQ · equity
DTIL price & chart
Loading TradingView…
NASDAQ:DTIL on TradingView ↗About the company
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of
In the news
No coverage from other publishers is available.
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 154,416,000Source | 136,388,000Source | 159,781,000Source | 238,169,000Source |
| Property, Plant and Equipment, NetUSD | 1,425,000Source | 3,089,000Source | 6,338,000Source | 20,190,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 1,166,000Source | 622,000Source | 400,000Source | 1,348,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 110,823,000Source | 85,899,000Source | 116,678,000Source | 189,576,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 0Source | 229,000Source | 901,000Source | 720,000Source |
| Assets, CurrentUSD | 118,740,000Source | 94,989,000Source | 136,359,000Source | 199,105,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,805,000Source | 7,090,000Source | 8,263,000Source | 2,974,000Source |
| Other Assets, NoncurrentUSD | 206,000Source | 221,000Source | 225,000Source | 2,570,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 62,168,000Source | 79,995,000Source | 140,920,000Source | 177,736,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 1,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -528,188,000Source | -482,464,000Source | -489,631,000Source | -428,312,000Source |
| Stockholders' Equity Attributable to ParentUSD | 92,248,000Source | 56,393,000Source | 18,861,000Source | 60,433,000Source |
| Additional Paid in Capital, Common StockUSD | 621,387,000Source | 539,808,000Source | 509,443,000Source | 489,696,000Source |
| Liabilities and EquityUSD | 154,416,000Source | 136,388,000Source | 159,781,000Source | 238,169,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 8,913,000Source | 14,980,000Source | 49,987,000Source | 59,664,000Source |
| Operating Lease, Liability, CurrentUSD | 1,507,000Source | 1,320,000Source | 1,133,000Source | 2,037,000Source |
| Accounts Payable, CurrentUSD | 296,000Source | 1,312,000Source | 2,968,000Source | 1,225,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,897,000Source | 6,404,000Source | 7,723,000Source | 2,776,000Source |
| Deferred Income Tax Liabilities, NetUSD | 1,263,000Source | 2,111,000Source | 3,277,000Source | 1,168,000Source |
| Other Liabilities, NoncurrentUSD | 259,000Source | 194,000Source | — | 201,000Source |
| Additional Financial Items | ||||
| Long-term DebtUSD | — | — | — | 22,223,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -45,724,000Source | 7,167,000Source | -61,319,000Source | -111,637,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,186,000Source | 12,604,000Source | 14,040,000Source | 19,197,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -229,000Source | -672,000Source | 181,000Source | 232,000Source |
| Increase (Decrease) in Accounts PayableUSD | -737,000Source | -2,096,000Source | 1,508,000Source | 153,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -65,843,000Source | -58,445,000Source | -84,114,000Source | -45,753,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -634,000Source | -215,000Source | 5,829,000Source | -3,319,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 95,162,000Source | 50,450,000Source | 5,387,000Source | 94,985,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 28,685,000Source | -8,210,000Source | -72,898,000Source | 45,913,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 137,153,000Source | 108,468,000Source | 116,678,000Source | 189,576,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,355,000Source | 1,738,000Source | 2,018,000Source | 824,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,186,000Source | 12,604,000Source | 14,040,000Source | 19,197,000Source |
| Amortization of Intangible AssetsUSD | 100,000Source | — | — | 100,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | -2,666,000Source | 258,000Source | 1,145,000Source | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | -2,666,000Source | 258,000Source | 1,145,000Source | -510,000Source |
| Gain (Loss) on Disposition of AssetsUSD | -421,000Source | -436,000Source | -461,000Source | -106,000Source |
| Gain (Loss) on Disposition of BusinessUSD | 855,000Source | — | 8,446,000Source | — |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | -421,000Source | -436,000Source | -563,000Source | -106,000Source |
| General and Administrative ExpenseUSD | 32,240,000Source | 35,299,000Source | 39,088,000Source | 41,525,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | 712,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | 200,000Source | 0Source | 10,800,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -46,609,000Source | 7,167,000Source | -42,527,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 885,000Source | 0Source | -18,792,000Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | -5,284,000Source | -1,084,000Source | -4,931,000Source | -1,579,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | 1,422,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -45,724,000Source | 7,167,000Source | -61,319,000Source | -111,637,000Source |
| Operating ExpensesUSD | 86,412,000Source | 94,858,000Source | 92,463,000Source | 125,464,000Source |
| Other Nonoperating Income (Expense)USD | 5,539,000Source | 33,329,000Source | 1,209,000Source | -11,271,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 4,986,000Source | 49,345,000Source |
| Proceeds from Noncontrolling InterestsUSD | 1,031,000Source | 905,000Source | — | 25,000,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | 31,000Source | 392,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 34,264,000Source | 68,696,000Source | 48,727,000Source | 25,098,000Source |
| Operating Income (Loss)USD | -52,148,000Source | -26,162,000Source | -43,736,000Source | -100,366,000Source |
| Other Nonoperating Income (Expense)USD | 5,539,000Source | 33,329,000Source | 1,209,000Source | -11,271,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -45,724,000Source | 7,167,000Source | -61,319,000Source | -111,637,000Source |
| Earnings Per Share, BasicUSD per share | -3.56Source | 1.05Source | -15.96Source | -1.27Source |
| Earnings Per Share, DilutedUSD per share | -3.56Source | 1.04Source | -15.96Source | -1.27Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 12,826,078Source | 6,832,982Source | 3,841,405Source | 87,898,498Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 12,826,078Source | 6,883,911Source | 3,841,405Source | 87,898,498Source |
| Interest Expense (non-operating)USD | 1,422,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 100,000Source | — | — | 100,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,468,000Source | 3,404,000Source | 6,817,000Source | 7,798,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | -2,666,000Source | 258,000Source | 1,145,000Source | -510,000Source |
| General and Administrative ExpenseUSD | 32,240,000Source | 35,299,000Source | 39,088,000Source | 41,525,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -46,609,000Source | 7,167,000Source | -42,527,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -45,724,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -3.63Source | 1.05Source | -11.07Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -3.63Source | 1.04Source | -11.07Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 885,000Source | 0Source | -18,792,000Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | -5,284,000Source | -1,084,000Source | -4,931,000Source | -1,579,000Source |
| Interest ExpenseUSD | — | 1,782,000Source | 2,230,000Source | 1,111,000Source |
| Interest Income, OtherUSD | 4,239,000Source | 6,763,000Source | 7,686,000Source | 3,473,000Source |
| Operating ExpensesUSD | 86,412,000Source | 94,858,000Source | 92,463,000Source | 125,464,000Source |
| Research and Development ExpenseUSD | 54,172,000Source | 59,559,000Source | 53,375,000Source | 83,939,000Source |
Filing attachments
a05272026ex991.htm · 8-K · 2026-05-27
EX-99.1 2 a05272026ex991.htm EX-99.1 Document Exhibit 99.1 Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 - New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts - - In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replic…
Read attachment ↗dtil-20260505ex991.htm · 8-K · 2026-05-05
EX-99.1 2 dtil-20260505ex991.htm EX-99.1 Document Exhibit 99.1 Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update - Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver Congress 2026 - - Advanced PBGENE-DMD toward clinical evaluation in the Phase 1/2 FUNCTION-DMD trial following U.S. FD…
Read attachment ↗dtil-20260312ex991.htm · 8-K · 2026-03-12
EX-99.1 2 dtil-20260312ex991.htm EX-99.1 Document Exhibit 99.1 Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity - - Strong Phase 1 ELIMINATE-B trial execution for PBGENE-HBV with 13 patients now dosed across first 5 cohorts; Data updates expected at medical c…
Read attachment ↗dtil-20251103xex991.htm · 8-K · 2025-11-03
EX-99 2 dtil-20251103xex991.htm EX-99.1 Document Exhibit 99.1 Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update Late-breaking oral presentation at the Liver Meeting® 2025 to feature new data from multiple cohorts of the Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B Commenced dosing in Cohort 3 of the ELIMINATE-B trial with additional data readouts planned in early 2026 Investigational new drug (IND) filing for PBGENE-DMD…
Read attachment ↗dtil-20250807xex991.htm · 8-K · 2025-08-07
EX-99.1 2 dtil-20250807xex991.htm EX-99.1 Document Exhibit 99.1 Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update Continued rapid progress with Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV for Hepatitis B; Announced safety and efficacy for Cohort 1 and safety data for Cohort 2 PBGENE-HBV demonstrated substantial antiviral activity in all Cohort 1 patients, with best responses achieving a 47-69% reduction in Hepatitis B surface antigen …
Read attachment ↗dtil-20250806xex991.htm · 8-K · 2025-08-06
EX-99 2 dtil-20250806xex991.htm EX-99.1 Document Exhibit 99.1 Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of complete cure Cohort 1, the lowest dose cohort (0.2 mg/kg) of…
Read attachment ↗